결핵 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Tuberculosis Diagnostics Market size is expected to reach USD 4.97 Million in 2034 from USD 2.94 Million (2025) growing at a CAGR of 6.03% during 2026-2034.

The tuberculosis diagnostics market is evolving rapidly as healthcare systems prioritize early detection and effective management of this infectious disease. Traditional diagnostic methods, such as sputum microscopy, are being supplemented and replaced by advanced molecular tests, interferon-gamma release assays, and rapid point-of-care solutions. Growing concerns over multidrug-resistant tuberculosis are accelerating adoption of highly sensitive and specific diagnostic tools.

Future developments will emphasize automation, miniaturization, and digital connectivity. Next-generation sequencing and AI-enhanced diagnostic algorithms are expected to improve accuracy, reduce turnaround times, and provide actionable insights for clinicians. Portable diagnostic platforms are gaining traction, particularly in low-resource settings, enabling decentralized testing and faster patient access to care. Integration of diagnostics with mobile health platforms is creating comprehensive systems for monitoring, surveillance, and treatment adherence.

The market outlook is reinforced by international health initiatives, government programs, and public-private partnerships aimed at eradicating tuberculosis. Rising investments in R&D for novel biomarkers and advanced imaging technologies are expected to further strengthen the diagnostic ecosystem. As innovation accelerates and global awareness increases, the tuberculosis diagnostics market is positioned to play a crucial role in reducing disease burden worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Detection of Latent Infection (Skin Test & IGRA)
• Phage Assay
• Detection of Drug Resistance (DST)
• Nucleic Acid Testing
• Radiographic Method
• Cytokine Detection Assay
• Others

By End-use

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

COMPANIES PROFILED

• Abbott, Qiagen, Thermo Fisher Scientific Inc, BD, F HoffmannLa Roche AG, Hologic Inc, Cepheid, DiaSorin SpA, Hain Lifescience GmbH, Oxford Immunotec
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Detection of Latent Infection (Skin Test & IGRA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Phage Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Detection of Drug Resistance (DST) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Nucleic Acid Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Radiographic Method Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Cytokine Detection Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL TUBERCULOSIS DIAGNOSTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott
  • 8.2.2 Qiagen
  • 8.2.3 Thermo Fisher Scientific Inc
  • 8.2.4 BD
  • 8.2.5 F. Hoffmann-La Roche AG
  • 8.2.6 Hologic Inc
  • 8.2.7 Cepheid
  • 8.2.8 DiaSorin S.P.A
  • 8.2.9 Hain Lifescience GmbH
  • 8.2.10 Oxford Immunotec